Transient visual loss due to reversible 'pending' central retinal artery occlusion in occult giant cell arteritis

Eye (Lond). 2014 Nov;28(11):1387-90. doi: 10.1038/eye.2014.181. Epub 2014 Aug 1.

Authors

M Sane¹, A Selvadurai², J Reidy¹, D Higgs³, F Gonzalez-Fernandez⁴, N Lincoff⁵

Affiliations

¹ Department of Ophthalmology, University at Buffalo, the State University of New York, Buffalo, NY, USA.
² Veterans Affairs Medical Center, Buffalo, NY, USA.
³ Department of Pathology and Anatomic Sciences, University at Buffalo, the State University of New York, Buffalo, NY, USA.
⁴ 1] Department of Ophthalmology, University at Buffalo, the State University of New York, Buffalo, NY, USA [2] Veterans Affairs Medical Center, Buffalo, NY, USA [3] Department of Pathology and Anatomic Sciences, University at Buffalo, the State University of New York, Buffalo, NY, USA.
⁵ Jacobs Neurological Institute, Buffalo, NY, USA.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Administration, Oral
Biopsy
Blindness / etiology*
Blindness / physiopathology
Blood Sedimentation
C-Reactive Protein / metabolism
Carotid Artery, Internal / diagnostic imaging
Carotid Stenosis / diagnostic imaging
Female
Fluorescein Angiography
Giant Cell Arteritis / complications*
Giant Cell Arteritis / drug therapy
Giant Cell Arteritis / physiopathology
Glucocorticoids / therapeutic use
Humans
Infusions, Intravenous
Methylprednisolone / therapeutic use
Middle Aged
Prednisone / therapeutic use
Retinal Artery Occlusion / complications*
Retinal Artery Occlusion / drug therapy
Retinal Artery Occlusion / physiopathology
Temporal Arteries / pathology
Ultrasonography, Doppler, Duplex

Substances

Glucocorticoids
C-Reactive Protein
Prednisone
Methylprednisolone

Grants and funding